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BakAn important mechanism in apoptotic regulation is changes in the subcellular distribution of pro- and anti-
apoptotic proteins. Among the proteins that change in their localization and may promote apoptosis are
nuclear proteins. Several of these nuclear proteins such as p53, Nur77, histone H1.2, and nucleophosmin were
reported to accumulate in the cytosol and/or mitochondria and to promote the mitochondrial apoptotic
pathway in response to apoptotic stressors. In this review, we will discuss the functions of these and other
nuclear proteins in promoting the mitochondrial apoptotic pathway, the mechanisms that regulate their
accumulation in the cytosol and/or mitochondria and the potential role of Bax and Bak in this process. This
article is part of a Special Issue entitled Mitochondria: the deadly organelle.ondria: the deadly organelle.
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Spatiotemporal protein translocation is a dynamic cellular process
used to regulate the activity and function of a wide variety of proteins,
which in turn regulate diverse and complex cellular events in health
and stressed cells. Translocation of proteins between subcellular
compartments is crucial for apoptosis regulation. For example, the
pro-apoptotic Bcl-2 family proteins, Bax and Bid, translocate from the
cytosol to the mitochondria where they promote the perforation of
the mitochondrial outer membrane (MOMP) ([1] and Kluck et al., in
this issue). This perforation facilitates additional apoptotic transloca-
tion events, such as the release of apoptogenic mitochondrial proteins
like cytochrome c, SMAC/DIABLO, and HtrA2/Omi, into the cytosol
where they promote caspase activation ([2] and [3]). Moreover,
during this process, the mitochondrial protein apoptosis-inducing
factor (AIF) and endonuclease G translocate to the nucleuswhere they
participate in DNA cleavage and nuclear condensation and fragmen-
tation [2]. Apart from the movement of proteins frommitochondria to
the cytosol or the nucleus, nuclear proteins have been shown to
translocate in the other direction, from the nucleus to the cytosol or to
mitochondria. This latter event has been proposed to play an
important role in many apoptotic systems. The aim of this review is
to summarize the current knowledge about the apoptotic effects of
nuclear proteins in the cytosol and/or on the mitochondria and todiscuss the potential mechanisms that control stress-induced nuclear
protein redistribution.
2. The effect of nuclear proteins on the mitochondria
Anumber of nuclear proteins have been shown to redistribute to the
cytosol and mitochondria at the onset of apoptosis. This redistribution
seems to occur prior to the release of mitochondrial proteins or the
activation of the apoptosome [4–7], and the action of these proteins in
the cytosol/mitochondria was therefore proposed to play an important
role in the apoptotic process (for reviews, see [8–13]).
2.1. The role of cytosolic/mitochondrial p53
2.1.1. p53 in apoptosis
p53 is a tumor-suppressor protein that accumulates in response to
DNA damage, oncogene activation, and other stresses and acts as a
nuclear transcription factor to regulate the expression of gene products
involved in cell cycle regulation, apoptosis, autophagy, and numerous
other processes. The transcription-dependent role of p53 in apoptosis
involves induction of pro-apoptotic genes (e.g., Bax, Puma, Noxa, and
Bid), or repression of anti-apoptotic genes (e.g., Bcl-2, Bcl-xL, and
survivin), respectively [14,15]. In addition to its transcriptional activity,
p53 was shown to exert a transcription-independent apoptotic activity
in the cytosol and/or onmitochondria. This was ﬁrst proposed byHaupt
et al., who showed that overexpression of a mutant form of p53, lacking
most of the DNA-binding domain (DBD) and therefore defective in
transactivation function, could nonetheless trigger apoptosis [16]. This
observation was supported by many subsequent studies showing that
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can efﬁciently induce apoptosis in human cells [17]. Furthermore,
activation of p53 was found to trigger apoptosis in the absence of RNA
andprotein synthesis [18] or the absence of a nucleus [19]. Lastly,mouse
embryonic ﬁbroblasts (MEFs) expressing a chimaeric p53 protein that is
capable of transactivation – yet lacks domains involved in transactiva-
tion-independent functions – was transcriptionally active and able to
induce cellular senescence, but not apoptosis [20].
2.1.2. Stress-induced accumulation and role of p53 in the cytosol and on
mitochondria
In line with a transcription-independent apoptotic activity of p53, a
variety of cell-death stimuli – ranging from DNA damage to hypoxia,
activated oncogenes, proteasome inhibition, and oxidative damage –
were shown to induce the accumulation of p53 in the cytosol and/or
on mitochondria [21–47]. The latter localization of p53 was associated
with cell death mediated byMOMP. Accordingly, it was shown that the
stress-induced translocation of p53 to the mitochondria precedes
changes in mitochondrial membrane potential, cytochrome c release,
and caspase activation [47]. Moreover, targeting ectopic p53 directly to
themitochondria induced cell death in some cell lines [21,23,25,47–50]
and puriﬁed p53 rapidly inducedMOMP and cytochrome c release from
isolated mitochondria in vitro [21–23,44,51].
The signiﬁcance of cytosolic/mitochondrial p53 in apoptosis is
further supported by studies with the small molecule, Piﬁthrin μ,
which inhibits p53 binding tomitochondria by reducing the afﬁnity of
p53 to the anti-apoptotic proteins Bcl-xL and Bcl-2, but hadno effect on
p53-dependent transactivation [37]. These studies showed that
Piﬁthrin μ protected thymocytes against radiation-induced apoptosisBax Anti
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Unfortunately, most of the data regarding the apoptotic role of
mitochondrial p53 were obtained from transformed rather than
primary cellular systems, and it was not determined if p53 was in its
wild-type or mutated form. Hence, it is unclear if the transcription-
independent effects of p53 on apoptosis are indeed attributed to the
physiologically relevantwild-type formof theprotein. In addition,many
of these studies employed wild-type p53 overexpressed as normal and
mitochondrially targeted version,whichmay have produced artefactual
cellular responses at sites where it might normally not accumulate.
2.1.3. The mechanisms whereby p53 triggers MOMP
How would p53 promote MOMP on mitochondria? MOMP is
thought to be promoted by the action of the “activated” pro-apoptotic
multidomain proteins (Bax and Bak) of the Bcl-2 family that can
homo-oligomerize and form pore-like supramolecular structures
within the outer mitochondrial membrane (OMM). MOMP is
inhibited by anti-apoptotic multidomain proteins of the Bcl-2 family
(such as Bcl-2, Bcl-xL, and Mcl-1). Bax and Bak are activated either by
their direct interaction with a subset of pro-apoptotic “BH3-only”
proteins (e.g., tBid and Bim) or by their release from anti-apoptotic
proteins by the neutralizing action of BH3-only proteins, which either
act as “sensitizers” or “de-repressors” (for a review, see [52–54], and
Andrews et al., in this issue). Current evidence suggests that the
transcription-independent pro-apoptotic function of p53 relies on its
interaction with several members of the Bcl-2 protein family (Fig. 1).
In this respect, p53 has been proposed to act like a BH3-only protein,
either by directly activating Bax and/or Bak or by binding to Bcl-2-likeBax
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Bak (for a review, see [13,55]). However, a proof that p53 is a BH3-
only protein is still missing. A BH3 domain in p53 has not yet been
identiﬁed and thus critical mutations in conserved amino acids of this
domain (Leu, Ile) have not yet been introduced to test if this ablates
p53 binding to Bcl-2 proteins and the ability of p53 to trigger MOMP
and apoptosis. Furthermore, it is somehow surprising that p53 has so
far not been found as binding partner of Bcl-2-like survival factors in
yeast two-hybrid screens. All bona ﬁde BH3-only proteins strongly
interact with Bcl-2 proteins in these assays (Christoph Borner,
unpublished results).
2.1.3.1. p53 and Bak. p53 was found to bind Bak in overexpression
studies. This interaction liberates Bak from pre-existing inhibitory
complexes with the anti-apoptotic Mcl-1 protein and promotes Bak
activation as indicated by Bak oligomerization and exposure of a
normally inaccessible N-terminal epitope—and cytochrome c release
[22]. Characterization of the p53–Bak interaction revealed that the
DBD of p53 is needed for binding to and oligomerizing Bak [22,51,56].
Notably, some p53 tumor-associated and transcription-impaired
mutants, point mutated in the DBD, were shown to bind Bak in vitro
and in vivo and to induce Bak oligomerization and cytochrome c
release from isolated mitochondria. However, when overexpressed in
human cancer cell lines, these p53 mutants did not exhibit apoptotic
activity [21,51]. These ﬁndings thus suggest that binding of p53 to Bak
may contribute to Bak activation, but it is clearly insufﬁcient to induce
apoptosis in vivo.
2.1.3.2. p53 and Bax. In vitro studies showed that p53 promotes the
oligomerization of recombinant Bax and the permeabilization of
artiﬁcial membranes and isolated mitochondria [23,44]. In addition,
cytosolic accumulation of p53 correlated with p53-dependent, but
transcription-independent, activation of Bax in vivo [12,27,30,38,57].
However, most studies (besides in stressed melanocytes [41,58])
failed to demonstrate physical association between p53 and Bax.
Thus a “hit-and-run” model was proposed to explain the functional
interaction between p53 and Bax [23]. In contrast to the DBD of p53,
which is needed for binding of p53 to Bak (and Bcl-2 and Bcl-xL, see
below), the N-terminus of p53, in particular its proline-rich domain
[23,57], is the region needed for p53-induced Bax activation.
Consistent with this, certain mutations in the DNA-binding domain
of p53 did not affect p53 ability to activate Bax in vitro and in vivo
[23,33,57].
As indicated above, models for the action of cytoplasmic p53 on
Bax and Bak are different and contradictory. Furthermore, there are
conﬂicting reports as to whether the effect of recombinant p53 on
isolated mitochondria requires the addition of recombinant Bax or
whether the presence of Bak, which is constitutively located within
the OMM, is sufﬁcient for the observed p53-mediated permeabiliza-
tion of mitochondria [21–23,44,51]. Thus, in vivo rather than in vitro
settings are needed to resolve the controversial impact of Bax versus
Bak in non-transcriptional p53-dependent apoptosis.
2.1.3.3. p53 and the anti-apoptotic proteins Bcl-2 and Bcl-xL. Biophy-
sical, co-immunoprecipitation, and NMR spectroscopy studies, as well
as molecular modeling, suggest that p53 binds to Bcl-xL and Bcl-2 by
electrostatic force/bonds via the p53 DBD [13,21,56,59–61] and that
mutations within the DBD of p53 impaired this binding [21,59]. By
contrast, a ﬂuorescence anisotropy study reported that Bcl-xL
interacts only with the core domain of p53 and not with the N-
terminal domain [56]. It should, however, be kept in mind that these
biophysical binding studies were carried out with truncated and/or
mutated versions of recombinant p53 and Bcl-2/Bcl-xL and thus these
in vitro studies might not represent the in vivo interaction of the full-
length proteins. Moreover, it seems contradictory that p53 mutants
lacking the DBD should perform transcription-independent apoptoticfunctions via Bcl-2 and Bcl-xL, if the same DBD is crucial for binding
p53 to these proteins.
How the Bcl-xL/Bcl-2–p53 interactions affect the apoptotic process
is unknown. Two models were proposed. The ﬁrst proposed by Moll
and colleagues suggests that binding of p53 to Bcl-xL and Bcl-2
neutralizes the inhibitory effect of the anti-apoptotic proteins on Bak
or Bax [21]. This model is supported by the ﬁndings that genotoxic
stress increases p53–Bcl-2 complexes and decreases Bcl-2–Bax
complexes [62]. Furthermore, the addition of puriﬁed p53 to
preformed Bcl-2–Bax or Bcl-xL–Bax complexes liberated Bax [23,62].
These results therefore suggest that binding of p53 to Bcl-2 and Bcl-xL
restrains the anti-apoptotic function of the latter and thereby leads to
Bak or Bax activation. However, how Bax/Bak is activated following
the p53-dependent restraining of the anti-apoptotic function of Bcl-2
and Bcl-xL is still unclear. A recent study suggested that binding of
p53 to Bcl-xL enhances the ability of BH3-only proteins to neutralize
the anti-apoptotic proteins [63]. In this respect p53 does not act like a
BH3-only protein, since it binds other domains in Bcl-xL than the
hydrophobic pocket. Using NMR spectroscopy and ﬂuorescence
polarization approaches, it was reported that binding of wild-type
(but not “hot spot” mutants) p53 DBD to Bcl-xL leads to structural
changes in the BH3 binding pocket (comprised of the BH123 regions)
of Bcl-xL. Furthermore, the afﬁnity of Bcl-xL for Bid BH3 peptide
increased in the presence of p53DBD, and Bcl-xL formed a ternary
complex with p53DBD and Bid BH3 peptide [63]. It was therefore
proposed that binding of p53 to the “bottom” side of Bcl-xL causes an
allosteric structural change within the BH3 peptide-binding groove
in Bcl-xL. This leads to opening of the groove and adaptation of a
conformation, which enhances binding of BH3-only proteins to Bcl-xL.
The authors therefore suggested that the p53 pro-apoptotic function
at the mitochondria is mediated by facilitating interaction between
Bcl-xL and BH3-only proteins, which in turn displaces Bax/Bak from
the anti-apoptotic proteins and consequently promotes MOMP.
However, this model does not explain how the ternary complex of
p53–Bclx-L–BH3-only protein displaces Bax/Bak from the anti-
apoptotic proteins.
A second model proposed by Green and colleagues argues that the
binding of p53 to the anti-apoptotic Bcl-2 proteins is not a death-
inducing signal but, rather, has an anti-apoptotic role by preventing
p53 from exerting its pro-apoptotic function. This model is supported
by the observation that, under physiological conditions, apoptosis
induction correlates with disruption of the Bcl-xL–p53 complex rather
than increasing the formation of the complex [64]. Such disruption
and liberation of p53 from the Bcl-xL–p53 complex were suggested to
result from binding of the BH3-only protein Puma (a transcriptional
target of p53) to Bcl-xL [64]. This notion was further supported by
experiments, which showed that a Bcl-xL mutant (G138A) that can
interact with p53 but not with Bax, Bak, or Puma, rendered cells
resistant to apoptosis induced by overexpression of p53, but not by
Bax, suggesting that the Bcl-xL binding to p53 indeed inhibits p53
apoptotic function [64]. Notably, however, transcription-independent
p53-mediated apoptosis was also observed in the absence of Puma
[30,44].
Further experiments are required to clarify the role of thep53–Bcl-2/
Bcl-xL complexes. For example, correlating the temporal changes in the
amounts of Bcl-xL–p53 and Bcl-2–p53 complexes in different in vivo
settings with distinct apoptosis events might give valuable insights.
2.1.3.4. Regulation of p53 transcription-independent apoptosis by other
mechanisms. Cytosolic p53 may also promote apoptosis by interacting
with non-Bcl-2 family proteins. For example, involvement of p53
in mitochondrial permeability transition pore (PTP) and vice versa was
also suggested. Stress-induced p53 localization at mitochondria was
reported to disrupt the integrity of the mitochondrial inner-membrane
by forming a complexwith cyclophilin D (a component of PTP complex)
[44]. On the other hand, blockingmitochondrial PTP using cyclosporine
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mitochondrial translocation suggesting thatmitochondrial permeability
transition is required for p53 mitochondrial translocation. [65].
Taken together, many proteins were proposed to interact with
cytosolic/mitochondrial p53 in apoptotic cells; however, to what
extent the interaction of p53 with each of the identiﬁed partners
contributes to apoptosis induction remains ill-deﬁned.
2.1.4. Cytosolic p53 and autophagy
Itwas also reported that normal levels of p53 inhibit basal autophagy
in unstressed cells and that this effect is mediated by cytoplasmic p53
[66]. How this is achieved is, however, poorly understood; nonetheless,
the autophagic and apoptotic activities of cytosolic p53 seem to be
mediated by different mechanisms since the p53 region required for its
cytoplasmic anti-autophagic functions does not require the DBD and
point mutations that affect the interaction of p53 with Bcl-2 family
proteins can still inhibit autophagy [67].
2.1.5. Additional functions of endogenous p53 in mitochondria
Mitochondrial p53 may have additional functions besides apopto-
sis (Fig. 2). In addition to its outer membrane localization, a sub-
fraction of p53 was found to localize inside the mitochondria by
forming a complexwith chaperone proteins such asmt-Hsp70 [47,68].
This intramitochondrial p53 seems to be involved in the transcription
and the replication of mitochondrial DNA (mtDNA). Accordingly, it
was shown that it interacts with mitochondria-speciﬁc DNA polymer-
ase γ (Pol γ) and consequently enhances the DNA replication activ-
ity of Pol γ. Therefore, intramitochondrial p53 may play a role in
maintaining the stability of the mitochondrial genome [69,70].
Moreover, p53 can bind directly the mtDNA [71] or the mitochondrial
base excision repair machinery (mtBER) to remove damaged bases
and stimulate the correct nucleotide incorporation [70,72]. In addition,
p53 is able to bind themitochondrial transcription factor A (mtTFA) in
order to regulate the mtDNA's transcription [73].
2.1.6. Mitochondrial targeting of cytosolic p53
p53 does not contain a classical mitochondrial translocation/
targeting motif. In addition, it seems that neither acetylation nor
phosphorylation plays a major role in mitochondrial targeting of p53
since no differences in phosphorylation/acetylation modiﬁcations of
nuclear and mitochondrial p53 proteins were observed following
stress [74]. It has been suggested that monoubiquitylation of p53
plays an important role inmitochondrial translocation [75]. According
to this model, a distinct cytoplasmic pool of monoubiquitinated p53,
generated in healthy cells by basal levels of MDM2 and similar E3
ligases, is subject in stressed cells to a rapid switch from polyubiqui-
tination and degradation fate, to mitochondrial translocation [24,75].
This model thus suggests that the source of mitochondrial p53 is not
nuclear but a separate and distinct stress-stabilized pool in the
cytoplasm. Once at mitochondria, p53 undergoes deubiquitination byP5
P53 mt TFA
P53 Pol γ
P53
mt D
Fig. 2. Non-apoptotic functions of mitochondrial p53. A sub-fraction of p53 can be localized
mitochondrial DNA (mtDNA). For details, see text.the ubiquitin hydrolase USP7/HAUSP, which generates the apoptoti-
cally active non-ubiquitinated p53 [75].
Other factors were proposed to regulate translocation of p53 to
themitochondria. For example, BakandBadwere proposed todirectp53
translocation to mitochondria or anchor it onto the surface of
themitochondrialmembrane [76],whereas nucleophosmin antagonizes
mitochondrial trafﬁcking of p53 [77]. The forkhead transcription factor
Foxo3a may also play a role in mitochondrial p53 effects since it was
shown to promote cytosolic accumulation of p53 and apoptosis by
increasing the associationof p53with thenuclearexportmachinery [78].
2.2. The role of cytosolic /mitochondrial Nur77
Nur77 (also known as TR3, NGFI-B, TIS1, and NAK-1) is an orphan
nuclear steroid receptor that belongs to the steroid/thyroid hormone
receptor superfamily, which acts as transcription factors (for a review,
see [79]). The physiological ligand for the Nur77 monomer and
homodimer has not been identiﬁed and might not be present, although
cytosporone B was shown to be a naturally occurring agonist for Nur77
[80]. Nur77 is highly expressed inmany cell types andwas implicated in
the regulation of cell proliferation and differentiation as well as
apoptosis. The important role that Nur77 plays in apoptosis is indicated
by the ﬁndings that Nur77 mRNA is rapidly induced in response to
various apoptotic stimuli in many cell types while inhibition of Nur77
expression or activity protected various cell systems from apoptosis
(for reviews, see [10,81] and references therein).
As a transcription factor, Nur77 regulates several downstream pro-
apoptotic genes, including TRAIL, Fas ligand, and NDG1 [82]. However,
it was suggested that translocation of Nur77 from the nucleus to
the mitochondria, rather than its DNA-binding and transactivation
activity, may be the mechanism whereby Nur77 promotes apoptosis.
This translocation was observed in many cell types including T-cells
[83,84], cutaneous T-cell lymphoma [85], prostate [86], breast [87],
colon [88], lung [89,90] ovary [91], liver [92], and gastric cancer cells
[93]. Furthermore, Nur77/TR3 nuclear-mitochondrial translocation
was found to be needed for apoptosis induced by various stimuli in
different cell types (e.g., [88,92,94]).
How does cytosolic Nur77 translocate to the mitochondria and
induce apoptosis? Like p53, Nur77 does not contain classical
mitochondrial targeting sequences. It was shown that in cancer
cell lines Nur77 interacts with Bcl-2 and that this interaction
mediates Nur77 targeting to the mitochondria. Furthermore,
binding of Nur77 to Bcl-2 induces a conformational change in Bcl-
2 that exposes its BH3 domain resulting in its conversion from a cell
death protector into a killer [95]. This Nur77 effect was also
conﬁrmed in other apoptotic systems such as negative selection of
thymocytes, where association of Nur77 with Bcl-2 and exposure of
the Bcl-2 BH3 domain was observed both in vitro and in vivo [84].
Thus, the mitochondrial pathway seems to mediate the apoptotic
effect of Nur77 [94,95].3
P53 mt BER
P53 mt Hsp70
NA
inside the mitochondria and to be involved in transcription, replication, and stability of
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apoptotic protein is in line with studies, which showed that the
phenotype of anti-apoptotic Bcl-2 proteins can be reversed in some
cellular contexts. For example, mutants of the Bcl-2-homolog Ced-9
appear to promote rather than prevent apoptosis in C. elegans [96] and
Bcl-2 homologs in Drosophila can manifest either cytoprotective or
cytodestructive phenotypes [97,98]. This phenotypic conversion
seems to involve the unstructured loop of Bcl-2, which links the BH3
and BH4 domains, since cleavage of the Bcl-2 loop by caspase-3 aswell
as a phosphorylation of the loop was suggested to convert Bcl-2 to a
pro-apoptotic form [99–101]. ThemechanismbywhichNur77 induces
such a conversion and how this promotes apoptosis is however still
unclear. It was suggested that the conformational change leads to the
exposure of the BH3 domain of Bcl-2 and that the converted Bcl-2may
then act as a BH3-only protein, which – either directly or indirectly –
induces Bax/Bak activation and the subsequent MOMP (Fig. 3). This
notion is supported by the observations that, in many cell systems,
Nur77-mediated apoptosis is accompanied by cytochrome c release
[93–95] and that in SK07-induced apoptosis, which seems to depend
on mitochondrial Nur77, the SK07-induced Bcl-2 conformational
change was associated with Bax activation [90]. Additional support
for a role of Bax/Bak in the Nur77/Bcl-2 effect comes from studies with
the NuBCP-9 peptide [102]. This 9 aa Nur77-derived peptide was
shown to stimulate apoptosis, to bind Bcl-2, and to induce a
conformational change in Bcl-2, which converts Bcl-2 to a pro-
apoptotic protein. Furthermore, the NuBCP-9-induced Bcl-2 confor-
mational change was shown to involve NuBCP-9 binding to the Bcl-2
loop, dislodgement of the Bcl-2 BH4 domain, and exposure of the BH3
domain. Importantly, induction of apoptosis by NuBCP-9 required the
expression of either Bax or Bak and was associated with their
activation. The addition of NuBCP-9 to Bcl-2 did not induce Bax-
dependent permeabilization of mitochondrial outer membrane lipo-
somes, arguing against a direct activationmechanism. Consistent with
an indirect activation mechanism, it was found that NuBCP-9 inhibits
the interaction of Bcl-2 with tBid, suggesting that NuBCP-9 may
indirectly induce Bax activation by inhibiting the interaction of Bcl-2
with BH3-only proteins. Furthermore, using the abovementioned
liposome system, it was shown that NuBCP-9 impaired the ability of
Bcl-2 or Bcl-xL to inhibit tBid-induced Bax activation, suggesting thatBAK
BAK
BAK
BAK
Bcl-2
Nur77 Bcl-2
Nur77 Bcl-2 BH3
Nur77
(a)
?
H1.2
(b)
Fig. 3. The effect of Nur77, H1.2, NPM, and PAR polymers on mitochondria. In response to ap
mitochondria and to promote MOMP. Nur77, H1.2, NPM, and PAR polymer directly translo
effectors (besides PAR polymers) interact with Bcl-2 family proteins. (a) Nur 77 binds to the
Bcl-2 and exposure of its BH3 domain. The conformationally changed Bcl-2 may act as a BH3-
NPM binds to cytosolic conformationally changed Bax. This binding may be involved in mitoc
release from the mitochondria by an unknown mechanism.the binding of NuBCP-9 to the loop domain prevents Bcl-2 from
binding to Bax/Bak. Interestingly, in addition to antagonizing the
survival function of Bcl-2, NuBCP-9 also inhibited the survival effect of
Bcl-xL probably due to neutralization of Bcl-xL by the conformationally
converted Bcl-2 [102].
2.3. The role of cytosolic/mitochondrial histone H1.2
ThenuclearproteinhistoneH1(H1.2) plays a key role in establishing
and maintaining higher order chromatin structure and in regulating
gene expression [103]. In addition to its roles in the nucleus, in response
to various apoptotic stimuli, mainly DNA damage, H1.2 translocates
from the nucleus to the cytoplasm [4,104–106] where it can trigger
MOMP [104]. Accordingly, Konishi and colleagues [104] identiﬁed H1.2
as a cytochrome c releasing agent presented in fractionated cytosolic
extract. Moreover, reducing H1.2 expression enhanced cellular resis-
tance to apoptosis and H1.2-deﬁcient mice exhibited increased cellular
resistance to apoptosis. ThemechanismwherebyH1.2 promotesMOMP
has not been determined. However, it seems to be mediated via a
conformational activation and oligomerization of Bak (Fig. 3) as
mitochondria from Bak-deﬁcient mice (which also do not contain Bax
due to its cytosolic localization) were relatively resistant to the
cytochrome c releasing effect of H1.2. Furthermore, this H1.2 effect
was blocked by the anti-apoptotic Bcl-2 family protein Bcl-xL.
HowH1.2 activates Bak onmitochondria is not known. Extranuclear
H1.2 exhibits a punctuated stainingpattern [4,104,105],which suggests,
but does not prove, that a fraction of the cytosolic H1.2 is localized to
mitochondria, where it may act on Bak or other mitochondrial com-
ponents. H1.2 neither possesses a BH3 domain nor any other signiﬁcant
homology with Bcl-2 nor can directly interact with Bcl-2 family
members [104]. Thus, if H1.2 acts on Bak, this is unlikely to bemediated
by the conventional mechanisms of activation of the multidomain pro-
apoptotic Bcl-2 family proteins. Therefore, it was suggested that H1.2
might activate Bak by directly disrupting the OMM [104]. However,
at present, there is no evidence to support this notion. Besides the effect
of H1.2 on Bak, it was suggested that cytosolic H1.2 may regulate
apoptosome formation. This is based on the observation that H1.2 can
form a protein complexwith Apaf-1, caspase-9, and cytochrome c upon
UV irradiation [107].NPM
Bax
Bax
Bax
Bax
AIF
Bax
N
PAR Polymers
(d)
(c)
optotic stimuli, Nur77, H1.2, NPM, and PAR polymers were shown to translocate to the
cate to mitochondria from the nucleus. On the mitochondrial membrane, the nuclear
loop region of Bcl-2, resulting in a rearrangement of the hydrophobic binding groove of
only protein. (b) H1.2 induces conformational activation and oligomerization of Bak. (c)
hondrial translocation and activation of Bax. (d) Mitochondrial PAR polymers cause AIF
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Nucleophosmin (NPM) is a multifunctional nucleolar phospho-
protein controlling vital cell processes such as ribosome biogenesis,
DNA repair, and RNA transcription [108]. In several systems, it was
shown that NPM redistributes to the cytoplasm in response to
apoptotic stimuli (e.g., [4,5,109–111]). In the cytosol, NPM may
participate in the mitochondrial apoptotic pathway by regulating
Bax activation (Fig. 3). Accordingly, it was reported that NPM
redistribution occurred before Bax translocation to the mitochondria.
In addition, in vitro studies show that NPM binds to conformationally
changed Bax and that Bcl-2 and p53 inhibited the Bax–NPM
interaction, implying that NPM may be involved in the translocation
of Bax to mitochondria [109,112]. NPM was also suggested to block
mitochondrial localization of p53 [77]. However, the mechanism that
underlies this NPM effect and whether it is mediated by nuclear or
cytosolic NPM was not elucidated.
2.5. The effect of PARP on mitochondria
Nuclear proteins may also indirectly act on the mitochondria. For
example, the nuclear protein poly(ADP-ribose) (PAR) polymerase-1
(PARP-1) can induce cell death in neurons via a mitochondrial action
of its PAR polymers products [113]. In cortical neurons, N-methyl-D-
aspartic acid (NMDA) treatment induced the generation of PAR
polymers, which translocate to the mitochondria were they promote
AIF release [114] (Fig. 3). Further studies showed that PAR polymers
induce cells death and AIF release in neurons as well as AIF release
from isolated mitochondria [115]. The cell death observed after PAR
delivery was size- and dose-dependent, but caspase-independent
[115]. It was therefore suggested that in parthanatos (a caspase-
independent cell death distinguished from apoptosis, necrosis, and
autophagy), free PAR polymer or poly(ADP-ribosy)lated acceptor
protein(s), produced by the excessive activation of PARP-1, translo-
cate to cytosol and mitochondria, where they interact with mito-
chondria and trigger AIF release [113]. The mechanism whereby PAR
polymer causes AIF release is not known. It was proposed that due to
its highly charged nature, it could depolarize mitochondria leading to
permeability transition and subsequent AIF release or that PAR
polymer could bind to mitochondrial PAR polymer binding proteins,
which then triggers AIF release [114].
2.6. The role of prohibitins on the mitochondria
Prohibitins (PHBs) constitute an evolutionarily conserved and
ubiquitously expressed family of proteins that are essential for cell
proliferation and development in higher eukaryotes. PHBs are mainly
localized to mitochondria as integral membrane proteins of the
mitochondrial inner membrane. Mitochondrial PHBs control cell
proliferation, cristae morphogenesis, and the functional integrity of
mitochondria. The mode of action of PHBs in the mitochondria
involves inter alia regulation of the cleavage of dynamin-like GTPase
OPA1, a protein known to regulate mitochondrial fusion and cristae
morphogenesis. It was shown that the absence of PHBs leads to
abnormal cristae morphology and increased sensitivity to apoptotic
stimuli [116,117]. Non-mitochondrial functions such as transcription-
al regulation and localization of PHBs to the nucleus were described in
several mammalian cell lines (for reviews, see [117,118]). Interest-
ingly, it was shown that in transformed cell lines (where PHBs are
mainly nuclear), apoptotic stimulation by camptothecin (but not
other stimuli, e.g., cisplatin and etoposide) induced the export of PHB
to perinuclear regions where it localized to mitochondria [119,120].
The camptothecin-induced PHB mitochondrial translocation corre-
lated with sensitivity to camptothecin-induced cell death as cells
that did not show this translocation were refractory to this type of cell
death. This suggests that the PHB translocation may regulate theapoptotic process [119]. However, a causal relationship was not
investigated and other factors could mediate the enhanced sensitivity
of the transformed cells to apoptosis. Moreover, it does not seem that
mitochondrial PHB promoted MOMP as indicated by the distinct
punctuated staining pattern of cytochrome c [119].
2.7. The role of caspase-2, Elk-1, APE/Ref-1, and FLASH
Additional nuclear factors were shown to redistribute to the
mitochondria in responses to apoptotic stimuli. (i) Caspase-2 is a
nuclear resident protein that was shown to trigger mitochondrial
dysfunction in an early phase of apoptosis. However, this effect occurred
without a relocalization of nuclear caspase-2 to the cytoplasm or
alterations of nuclear pores or the nuclear/cytoplasmic barrier [121]. (ii)
The transcription factor Elk-1 was shown to be localized to the nucleus
as well as the mitochondrial PTP complex. Furthermore, its mitochon-
drial association was increased in response to apoptotic stimuli [122].
(iii) The base excision repair (BER) enzyme APE/Ref-1 is a DNA repair
enzyme, which is mainly localized in the nucleus. In the B-lymphocyte
Raji cells a fraction of APE/Ref-1 was shown to rapidly redistribute to
mitochondria followingH2O2 activation. However, targeting of APE/Ref-
1 to mitochondrial was not associated with cytochrome c release or
apoptosis induction suggesting that the oxidative stress-induced APE/
Ref-1 translocation to the mitochondria might exert a protective
function [123]. (iv) Caspase-8-binding protein FLICE-associated huge
protein (FLASH) is a large protein with a calculated molecular mass of
220 kDa. FLASH has several potential nuclear localization signal (NLS)
sequences and was shown to localize mainly in nuclear bodies. In
response to CD95 activation FLASH exits the nucleus and translocates to
mitochondria where it interacts with mitochondria-associated pro-
caspase-8 and promotes caspase-8 activation, suggesting that the death
receptor CD95 can also signal via a nuclear pathway [124].
3. Regulation of nuclear export during apoptosis
3.1. Nuclear transport
How are nuclear proteins transported to the cytoplasm/mito-
chondria? The basic mechanisms underlying nucleocytoplasmic trans-
port have been characterized and comprehensive reviews are available
(e.g., [8,125–128]). In short, nuclear transport proceeds through nuclear
pore complexes (NPCs). Transport through the NPCs may occur either
by passive diffusion, according to the concentration gradient across the
nuclear envelope, or actively, in a signal- and energy-dependent
manner. Passive transport is restricted to macromolecules smaller
than 50–40 kDa, whereas active transport can accommodate up to
several million Daltons (Da) in size. The active nuclear transport
pathway is mediated by importin β-type nuclear transport receptors,
which include nuclear export receptors (exportins), as well as
importins. These receptors bind cargoes directly or through adapter
molecules, shuttle constantly between the nucleus and cytoplasm, and
use the chemical potential of the nucleocytoplasmic GTP-bound Ran
(RanGTP) gradient to act as unidirectional cargo pumps. Exportins
recruit cargo at high RanGTP levels in the nucleus, traverse NPCs as
ternary cargo–exportin–RanGTP complexes and release their cargo
upon GTP hydrolysis into the cytoplasm. Chromosome region mainte-
nance 1 protein (Crm1) (also known as exportin 1, Xpo1) and CAS (also
known as Cse1p, exportin2) [129] are the prototypical exportins. Crm1
mediates nuclear export of numerous cargoes, which carry a short
leucine-rich nuclear export signal (NES) or export signatures that
include foldeddomains. CAS is specialized to retrieve the nuclear import
adapter importin α back to the cytoplasm. Crm1 binds RanGTP, export
substrates, and nucleoporins to target the substrates to the NPCs. In the
cytoplasm, GTP hydrolysis and consequent dissociation of Ran from
Crm1 releases low-afﬁnity substrates, while additional factors facilitate
release of high-afﬁnity substrates.
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of nuclear proteins
Fig. 4 summarizes and illustrates the pathways whereby the
different nuclear components translocate from the nucleus to the
cytosol.
3.2.1. Cytosolic/Mitochondrial accumulation of p53
p53 contains both NLS and NES sequences [130–132]. The nuclear
localization of p53 protein is initiated by binding to importin α/β
[133,134], whereas p53 nuclear export requires Crm1 binding. Multiple
posttranslational modiﬁcations control the nuclear versus cytoplasmic/
mitochondrial localization of p53. In healthy cells, basal p53 level is
maintained via MDM2-induced polyubiquitination and degradation by
theproteasome [135,136]. In addition,MDM2also regulatesp53nuclear
export. MDM2-mediated monoubiquitination of the C-terminus of p53
reveals its NES, enhances sumoylation in this region, and promotes
nuclear export by a Crm1-dependent manner [137–140]. Low levels of
MDM2 are associated with monoubiquitination and nuclear export,
whereas higher MDM2 levels support polyubiquitination and degrada-
tion of p53 [35,78]. Once in the cytoplasm, the majority of p53 is
degradedby theproteasome;however, low levels of p53are still present
in normal tissues. Although monoubiquitination of p53 by MDM2
contributes to p53 nuclear export [25,141,142], itwas also reported that
the NES of p53 by itself is capable to promote cytosolic localization of
p53 in a MDM2-independent manner [131].
In response to stress, p53 rapidly accumulates in the nucleus either
by import [134] or by its retention due to the impediment of MDM2-
mediated cytosolic translocation and masking of the C-terminal NES
[131]. Furthermore, a distinct cytoplasmic pool of p53 translocates to
mitochondria upon its stress-induced stabilization.
In addition to ubiquitination other posttranslation modiﬁcations
regulate p53 subcellular localization. For example, phosphorylation
of p53 regulates its nuclear accumulation. Phosphorylated p53 is
unable to leave the nucleus because the phosphorylation inhibits the
availability of the N′ terminal NES sequence or MDM2 binding [132].
Furthermore, phosphorylated p53 interacts with PARP-1. This
interaction masks the p53 NES signal, thereby preventing its nuclear
export [143,144]. In addition, poly(ADP)ribosylation of p53 by PARP-1
leads to p53 nuclear accumulation [145].H1.2
PAR Polymers
(e)
NPM N
CrmCrm1
NPMH1.2
PAR Polymers
Passive or active
PHB
PHB
NES
Crm1
FLASH
FLASH
Crm1
Fig. 4. Summary of the pathways whereby nuclear pro-apoptotic components are transporte
(except p53, that its cytosolic fraction is the fraction that mediates its effect on the mitochAnother posttranslation modiﬁcation that regulates p53 sub-
cellular localization is acetylation, which acts by inhibiting MDM2-
induced p53 ubiquitination [146]. This effect seems to be regulated by
the number of acetylated residues. When fewer than three lysines
residues are acetylated, p53 will be stabilized in the nucleus. If more
than four lysines residues are acetylated p53 will be exported to the
cytoplasm [147]. A role of acetylated p53 in the cytosolic/mitochondrial
effect of p53 is supported by a study, which shows that the Lys120-
acetylated isoform of p53 is enriched at mitochondria and that this
acetylation is important to displace Mcl-1 from Bak [148]. However,
other study suggests that nuclear p53 is acetylatedwhereas cytoplasmic
p53 is deacetylated [149]. Thus the role of acetylation in p53 subcellular
distribution still needs to be unraveled.
3.2.2. Mechanism of Nur77 translocation from the nucleus
The apoptosis-induced Nur77 nuclear export is mediated via the
Crm1 export pathway since it was blocked by the Crm1 inhibitor
leptomycin B (LMB) (e.g., [84,88,94,150,151]). This transport requires
dimerization with the retinoid X receptor α (RXRα) [89,152]. The
nuclear export of Nur77/RXRα is then mediated through Crm1 by a
NES located in the ligand binding domain of RXRα [89].
Posttranslation modiﬁcation also regulates Nur77 nuclear export
and translocation to themitochondria.Nur77/TR3 is heavily phosphory-
lated in vivo on multiple sites [153]. It was shown that MEK-ERK-RSK
cascade via phosphorylation of Nur77 by RSK at serine 354 regulates
Nur77 nuclear export and translocation to mitochondria during T cells
death [83]. On the other hand, phosphorylation of cytoplasmic Nur77 at
its N-terminus by Akt inhibited apoptosis, prevented Nur77 mitochon-
drial targeting, and promoted the disassociation of Nur77 from Bcl-2
[154]. The nucleus-to-mitochondria translocation of Nur77 can also be
regulated by nuclear proteins, which interact with Nur77. For example,
it was reported that Nur77 interacts with the oncogene chromodomain
helicase/adenosine triphosphataseDNA-bindingprotein1-like (CHD1L)
or Epstein-Barr virus nuclear antigen. Binding of Nur77 to theseproteins
retains Nur77 in the nucleus [155,156].
3.2.3. Mechanism of H1.2 translocation from the nucleus
How nuclear H1.2 redistributes to the cytosol following stress is
unclear. No canonical NES was identiﬁed in the H1.2 sequence.
Furthermore, posttranslational modiﬁcation does not seem to play aES
Nur77
Crm1
Nur77 RXRα
P P
Nur77 RXRα
P P
1
RXRα
d from the nucleus to the cytosol during apoptosis. The scheme includes all the proteins
ondria) and PAR oligomers that were described in the review. For details, see text.
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any obvious posttranslational modiﬁcations as a result of DNA damage,
and the nuclear and cytoplasmic forms of H1.2 are indistinguishable
[157]. DNA damage may dislodge some H1.2 from the chromatin. This
dislodged population may then, by an unknown mechanism, be
available for Crm-1 mediated (LMB-sensitive) nuclear export system
[104].
3.2.4. Mechanism of NPM translocation from the nucleus
Sequence analysis ofNPMorthologues indicated the presence of NES
as well as NLS motifs. In healthy cells, NPM can shuttle between the
nucleus and cytoplasm, by a Ran–Crm1-dependent pathway that is
mediated through the NPM's NESmotif [158]. Notably, in acutemyeloid
leukemia with normal karyotype (AML-NK), NPM mutants were
described that are aberrantly localized in the cytoplasm. This cytosolic
accumulation was inhibited by Crm1 inhibitors and resulted from the
generation of an additional NES motif in the mutants (for a review, see
[159] and references therein). However, themechanismwhereby stress
induces NPM cytosolic translocation has not been explored.
3.2.5. Mechanism of PAR translocation from the nucleus
How do PAR polymers translocate from the nucleus to the cytosol/
mitochondria? It is not yet clear whether the toxic polymers exit the
nucleus as free molecules or associated with a protein carrier. In the
experiments where free PAR polymers were used as death-promoting
agents, the 60-mer, corresponding to a molecular weight of about
33 kDa [9], was the most efﬁcient cell death inducer [114,115]. In this
case, the redistribution of PAR polymers may progress by passive
diffusion. This notion is further supported by the observation that in
response to glutamate (an agonist of the NMDA receptor) theFig. 5. Models for sequential stress/apoptosis-induced alteration in the NPCs. In healthy ce
molecules up to ~40 kDa can diffuse freely through the NPC, whereas larger molecules ar
apoptosis, the size-exclusion limit of the NPC increases, leading to the passive diffusion of m
accompanied by the accumulation of Ran and importins in the cytoplasm and nucleus, resp
export of mitochondria-targeted apoptogenic nuclear proteins (NPs) is expected to occur eff
may involve calcium. At a later stage of apoptosis, when proteases such caspases and/or calp
proteases and distinct Nups are cleaved. The caspase cleavage leads to the degradation of m
leads to the degradation of most FXFG-containing Nups. The protease-mediated cleavage of
overall structure of the pore remains intact. Thus, some nuclear proteins may still be expor
both stages) is expected to facilitate both entry and exit of molecules into and out of the npermeability of neuronal NPCs is increased [160]. Alternatively, PAR
polymers may be transported while being attached to proteins.
Hereby, their shuttling may be regulated by the active export system.
3.2.6. Mechanism of translocation PHB, FLASH, and caspase-2-derived
factor from the nucleus
The camptothecin-induced PHB translocation from the nucleus to
the cytosol/mitochondria observed in transformed cell lines [119,120]
was mediated by the Crm1-dependent (LMB inhibitable and physical
interaction with Crm1) export pathway and required a NES at the
C-terminal region of PHB. The CD95-induced nucleocytoplasmic
translocation of FLASH required CD95-induced caspase activation
and was facilitated by the Crm1-dependent nuclear export pathway.
The indirect effect of caspase-2 on the mitochondria was Crm1-
independent since LMB did not interfere with this effect [121].
3.3. Increased permeability of NPC during apoptosis
Several mechanisms may lead to the stress-induced accumulation
of nuclear proteins in the cytosol: (i) release of nuclear proteins from
the nucleus to the cytosol, (ii) inhibition of nuclear import, and
(iii) stabilization of the cytosolic fraction of the protein. The latter
was suggested to occur in the case of p53 (see above). However, the
other two mechanisms may also play a role. If a nuclear protein is
translocated from the nucleus to the cytosol as proposed, for example,
for Nur77 and H1.2 (see above), this process is expected to involve at
least two steps. First, stress-induced dislodgement of the protein from
its interaction(s) with nuclear binding partner(s) and/or enhance-
ment of the accessibility of the nuclear protein to the active transport
pathway (e.g., exposure of an NES site). This process can be mediatedlls, molecules (Mol) are transported in and out the nucleus through the NPCs. Small
e actively transported by the receptor mediated passage system. At an early phase of
edium size molecules (about the size of 70 kDa dextran). This increased permeability is
ectively [5]. At this stage, the structure of the NPCs remained intact and thus the active
ectively. The mechanism that increases the NPCs permeability barrier is not known but
ain are activated, the nuclear pore proteins [nucleoporins (Nups)] are attacked by these
ost of the peripheral Nups and two NPCs core Nups. In excitotoxicity, calpain activation
nucleoporins is expected to inhibit active transport; however, despite this cleavage, the
ted by the active transport system. Notably, the enhanced permeability of the NPCs (at
ucleus respectively.
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where its phosphorylation by RSK regulates nuclear-mitochondrial
translocation of Nur77 during apoptosis [83]. The dislodgement and
enhanced accessibility step probably depends on the type of the stress
and the nature of the interactions between the proteins and the
nuclear components. Indeed we observed that the redistribution (e.g.,
rate and extent) of nucleolin, NPM, and histone H1 (H1) in WT MEFs
was stress-dependent (Lindenboim L, Borner C, and Stein R,
unpublished results). In analogy, it was shown that translocation of
nuclear proteins from the nucleolus to the nucleoplasm depends on
the type of the DNA damage employed [11]. Once the proteins are
freed from their restrained interactions they can be released from
the nucleus. This release, however, is unlikely to occur by nuclear
membrane perforation since nuclear membranes remain intact during
apoptosis [7,161,162] but by an alteration in the permeability of the
NPC (for review, see [8,9]). The alteration in the NPC permeability was
proposed to occur by two sequential steps (Fig. 5). Accordingly, at
early time points of apoptosis induction, a caspase-independent
increase in the diameter of the NPC channel occurs, which enables the
concomitant passive diffusion of small-sized molecules as well as a
redistribution of essential nuclear transport factors such as Ran and
importinα and importin β [6,160,163]. The mechanism that regulates
this increase in NPC permeability is still unknown but may involve
calcium. For example, changes in nuclear calcium levels were shown
to modulate the passage of intermediate sized dextrans (10–70 kDa)
through the NPC [164], to alter the NPC structure [165] and to
promote cytoplasmic shuttling of phospholipase C-delta [166]. In the
next step, which occurs later in the apoptotic process, proteases such
caspases [167–170] and calpains [160] cleave deﬁned subsets of
components of the NPC, a process that may further increase the
leakiness of the nuclear barrier and facilitate redistribution of larger
proteins across the nuclear envelope [6,7,124,160,169,170]. Notably,
although this cleavage leads to the degradation of most of the
peripheral NPC proteins and two NPC core proteins [8,169,171], it
does not completely dismantle the NPC as indicated by the preserved
morphology of apoptotic NPC visualized by transmission electron
microscopy [160,170,172,173]. Although the mechanismwhereby the
permeability of the NPC is increased is still largely unknown, it seems
that the second step depends on the collapse of the permeability
barrier occurring in the ﬁrst step, which enables caspases and/or
calpain to diffuse through the NPC into the nucleus and to cleave their
NPC substrates. It should be noted, however, that active transport
was suggested to mediate the cytosolic/mitochondrial redistribution
of at least some of the nuclear pro-apoptotic proteins, e.g., Nur77 and
H1.2 (see above). In view of the ﬁndings that the mitochondrial
redistribution of these proteins may indeed be required for MOMP
[94,104], it is reasonable to assume that the redistribution occurred
before the caspase-dependent degradation of the NPC. However,
the relationship between the NPC permeability barrier and the
redistribution of Nur77 and H1.2 has not been determined. Thus,
the possibility that active transport of these proteins occurs before
alterations of NPC composition, by a mechanism that makes these
proteins available to the active transport machinery cannot be
excluded. Alternatively, it is possible that the alteration in the NPC
permeability does not abrogate active transport across the NPC and
thus the combined action of the availability of nuclear proteins to the
active transport system as well as the enhanced NPC permeability
may lead to an accelerated nuclear export. Another explanation for
the stress-induced appearance of nuclear proteins in the cytoplasm
might be a decreased rate of active import. This may account, for
example, for proteins whose cytoplasmic accumulation is not
suppressed by Crm1 inhibitors and which are too big to passively
diffuse through the NPC. The observation of impaired distribution of
Ran, importin α, and importin β at an early apoptotic stage may
support this putative mechanism [6], since this process is expected
to inhibit the import of classical-NLS dependent substrates to thenucleus due to the absence of importins in the cytosol [8]. Later in the
apoptotic process when caspases are activated, additional nuclear
proteins may translocate to the cytosol/mitochondria, where they
may participate in the apoptotic process. Such a proteinmay be FLASH
whose redistribution was caspase-dependent [121].
Which of these mechanisms are mainly acting in stress-induced
nuclear protein redistribution is currently unknown. Although we
cannot exclude the possibility that each nuclear protein is
transported by a distinct mechanism, the observation that many
proteins undergo nucleocytoplasmic shuttling during apoptosis and
that several nuclear proteins are redistributed in the same apoptotic
cell (Lindenboim L, Borner C, and Stein R, unpublished results)
suggests a common mechanism. It should be noted, however, that
not all nuclear proteins are redistributed in response to stress
[4,174–177]. Thus, if a common mechanism exists, then the
selectivity of the redistribution may rely on the availability of the
protein to this common pathway.
3.4. The role of Bax/Bak in nuclear protein redistribution
How the apoptotic signals converge to the redistribution machinery
is still unknown. A recent study from our own laboratories, however,
suggests that the multidomain pro-apoptotic Bcl-2 family proteins Bax
and Bak are involved [4] for the following reasons: (i) MEFs deﬁcient in
Bax and Bak did not exhibit redistribution of the nuclear proteins H1,
NPM, and nucleolin; (ii) the BH3 mimetic ABT-737, which is known to
act via Bax/Bak, also induced the redistribution effect in a Bax/Bak-
dependentmanner; and (iii) re-expression of Bax or Bak in the Bax/Bak
DKO MEFs restored the redistribution effect. Importantly, the nuclear
redistribution effect was not accompanied by Bax or Bak N-terminus
exposure (an indication of activation-associated conformational
changes of Bax or Bak) and was not inhibited by Bcl-xL overexpression,
suggesting that the effect of Bax/Bak on nuclear protein redistribution is
not mediated by the canonical Bax/Bak pore-forming activity on the
MOM [4]. The question arises on how Bax/Bak would regulate nuclear/
cytoplasmic redistribution/transport from their site of action (mito-
chondria, ER, nucleus). It is possible that Bax/Bak trigger a yet
unidentiﬁed caspase-independent signaling pathway, which either
increases the permeability of the NPCs or impairs active nuclear import.
In the former case, the signaling pathway may be calcium-dependent
since it has been shown that the Bax and Bak regulate resting
concentration of calcium in the ER [178]. Another possibility is that a
pore-forming activity of Bax/Bak on the nuclear envelop may mediate
the redistribution effect. Consistentwith this notion, and other potential
nuclear-targeted actions of Bax/Bak, are the observations that anti- and
pro-apoptotic Bcl-2 family proteins (including Bax) can reside in the
nucleus, on the nuclear membrane or at the nuclear pore [179–184].
Further studies are required to elucidate the mechanism whereby Bax/
Bak regulates nuclear protein redistribution.
With respect to the role of cytosolic H1.2 and NPM in apoptosis, it
should be noted that their effects were suggested to be mediated via
Bax/Bak [13,104,105,109,112]. However, the ﬁnding that the appear-
ance of H1 and NPM in the cytosol is mediated via Bax/Bak implies
that Bax/Bak acts upstream of H1.2 and NPM and thus regulates the
ability of these nuclear proteins to activate them.
4. Concluding remarks
Stress-induced redistribution of nuclear proteins to the cytosol/
mitochondria was suggested to play an important apoptotic role. Most
of the nuclear proteins shown to redistribute to the mitochondria
were suggested to promote apoptosis via MOMPmainly by regulating
the Bcl-2 family of proteins (Figs. 1 and 3) suggesting that this
redistribution effect, which occurs early in the apoptotic cascade, is
one of the pathways that regulates the action of the Bcl-2 proteins
family on the mitochondria.
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redistribution [4] suggests that these pro-apoptotic proteins may
regulate MOMP by two consequential steps: ﬁrst, by promoting
nuclear protein redistribution and then, following their activation by
the action of the redistributed protein, by directing MOMP. The
existence of such two distinct steps may be supported by the ﬁnding
that the nuclear protein redistribution effect is not associated with
Bax/Bak N-terminal exposure and is not inhibited by Bcl-xL [4]. The
stress-induced redistribution effect involves both an active transport
as well as passive diffusion due to an increase in the permeability of
the NPC (Fig. 5). The mechanisms that govern these effects are largely
unknown and further studies are needed to elucidate them.
The key question for each nuclear protein translocating to the
cytosol/mitochondria at an early step in apoptosis is whether it plays an
active role (positive or negative) in the apoptotic programor represents
just an epiphenomenon. A conclusive answer to this question may not
be easy, as studying a dying cell poses a fundamental challenge in
discriminating between causes and effects. Moreover, it is likely that
several proteins are redistributed in the same cell during the apoptotic
process, which makes it difﬁcult to dissect the role of each protein.
Furthermore, it is possible that additional unknown proteins are
exported and, moreover, we cannot exclude the possibility that at
least some of them would have anti-apoptotic effects. Nonetheless, at
least in the case of theproteinsdiscussed in this review (e.g., p53, Nur77,
and H1.2), it appears that they participate in the promotion of the
apoptotic process.Acknowledgments
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